LETTER FROM THE CHAIRPERSONS
Dear Colleagues:
As the field of tumor angiogenesis and anti-angiogenic therapy continues to undergo explosive growth, the 11th International Symposium on Anti-Angiogenic Agents provides current and useful information to basic scientists, clinical investigators, and those who practice oncology. This year’s symposium has been developed to focus on the most recent advances in basic biology and preclinical and clinical development of anti-angiogenic therapies. This novel symposium, addressing both basic and clinical research, continues to be recognized as the largest international symposium of its kind. Highlights of the 2009 symposium include the following:
- In-depth presentations on novel biologic advances in angiogenesis research
- A review of new and emerging targets for anti-angiogenic therapy
- An update on the early stages of clinical development of new anti-angiogenic therapies
- A debate on the value of biomarkers
- The latest results from clinical trials investigating anti-angiogenic therapies for the management of patients with colorectal, breast, lung, pancreatic, genitourinary, neuroendocrine, hepatocellular, CNS, ovarian and prostate cancers, as well as leukemias, lymphomas, and other types of tumors
- An overview of anti-angiogenic related toxicities and strategies for patient management
As in years past, we are pleased to have confirmed leaders in the fields of biology, hematology, and oncology who are actively involved in the investigation of angiogenesis and methods to inhibit this process. In addition to faculty plenary presentations, the symposium will also host a poster session from which several abstracts will be chosen for presentation at the plenary session. All attendees are strongly encouraged to submit abstracts to be considered for poster presentations.
For further information, including instructions regarding program registration and online abstract submission, please call 646-416-5150.
We look forward to your participation in what promises to be an exciting and educational symposium.
Sincerely,
Lee M. Ellis, MD
Professor of Surgery and Cancer Biology
William C. Liedtke, Jr., Chair in Cancer Research
Chair, Ad Interim, Department of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Robert S. Kerbel, PhD
Canada Research Chair in Tumor Biology,
Angiogenesis and Antiangiogenic Therapy
University of Toronto
Senior Scientist, Molecular and Cellular Biology Research
Sunnybrook Health Sciences Centre/Odette Cancer Centre
Toronto, Ontario, Canada
Michael S. Gordon, MD
Clinical Associate Professor of Medicine
University of Arizona College of Medicine
Premiere Oncology of Arizona
Scottsdale, Arizona
George W. Sledge Jr, MD
Ballvé-Lantero Professor of Oncology
Co-Director, Breast Cancer Program
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana